stockrowAxsome Therapeutics, Inc.
AXSM Healthcare Biotechnology
Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +73.9%
- Free cash flow
- −1,078.3%
- Total debt
- +4.04%
Quarter to September 2026, against a year earlier
Follow AXSM
Alert me
Axsome Therapeutics, Inc. (AXSM) Net income
Axsome Therapeutics, Inc.'s net income for fiscal 2025 was −$183.2M, compared with −$287.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$157.3M. Over the past ten years it has ranged from −$287.2M (fiscal 2024) to −$12.2M (fiscal 2015); the current reading is higher than 36% of that period. Axsome Therapeutics, Inc. ranks 490th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$183.2M | — |
| FY2024 | −$287.2M | — |
| FY2023 | −$239.2M | — |
| FY2022 | −$187.1M | — |
| FY2021 | −$130.4M | — |
| FY2020 | −$102.9M | — |
| FY2019 | −$68.3M | — |
| FY2018 | −$31.0M | — |
| FY2017 | −$28.9M | — |
| FY2016 | −$27.2M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$12.9M | — |
| Jun 2026 | −$51.3M | — |
| Mar 2026 | −$64.5M | — |
| Dec 2025 | −$28.6M | — |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $51.5M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$77.6M |
| ORKA Oruka Therapeutics, Inc. compare | −$132.9M |
| AXSM Axsome Therapeutics, Inc. | −$157.3M |
| RYTM Rhythm Pharmaceuticals, Inc. compare | −$193.8M |
| PRAX Praxis Precision Medicines, Inc. compare | −$339.1M |
| ABVX Abivax SA Sponsored ADR compare | −$458.7M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$565.2M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$903.9M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on AXSM
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement